Topic: age-related macular degeneration

Novartis headquarters

8. Brolucizumab

Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, respectively, and they may have more company later this year. 

4. Novartis

To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.

2. Roche

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.